Zimmer Biomet Holdings Inc (ZBH) : Tpg Group Holdings (sbs) Advisors reduced its stake in Zimmer Biomet Holdings Inc by 75.59% during the most recent quarter end. The investment management company now holds a total of 7,351,710 shares of Zimmer Biomet Holdings Inc which is valued at $863.4 Million after selling 22,766,850 shares in Zimmer Biomet Holdings Inc , the firm said in a disclosure report filed with the SEC on May 13, 2016.Zimmer Biomet Holdings Inc makes up approximately 9.01% of Tpg Group Holdings (sbs) Advisors’s portfolio.
Other Hedge Funds, Including , Auxier Asset Management reduced its stake in ZBH by selling 150 shares or 0.18% in the most recent quarter. The Hedge Fund company now holds 83,814 shares of ZBH which is valued at $9.8 Million. Zimmer Biomet Holdings Inc makes up approx 2.33% of Auxier Asset Management’s portfolio.Amalgamated Bank boosted its stake in ZBH in the latest quarter, The investment management firm added 1,651 additional shares and now holds a total of 6,173 shares of Zimmer Biomet Holdings Inc which is valued at $724,957. Zimmer Biomet Holdings Inc makes up approx 0.07% of Amalgamated Bank’s portfolio.Schulhoff Co Inc reduced its stake in ZBH by selling 160 shares or 5.58% in the most recent quarter. The Hedge Fund company now holds 2,705 shares of ZBH which is valued at $313,158. Zimmer Biomet Holdings Inc makes up approx 0.20% of Schulhoff Co Inc’s portfolio.
Zimmer Biomet Holdings Inc opened for trading at $121.2 and hit $122.27 on the upside on Wednesday, eventually ending the session at $121.93, with a gain of 0.97% or 1.17 points. The heightened volatility saw the trading volume jump to 15,92,999 shares. Company has a market cap of $24,293 M.
On the company’s financial health, Zimmer Biomet Holdings Inc reported $2.00 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.93. The company had revenue of $1904.00 million for the quarter, compared to analysts expectations of $1878.31 million. The company’s revenue was up 67.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.54 EPS.
Many Wall Street Analysts have commented on Zimmer Biomet Holdings Inc. Company shares were Reiterated by Barclays on Apr 29, 2016 to “Overweight”, Firm has raised the Price Target to $ 135 from a previous price target of $130 .Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 132 from a previous price target of $120 .Zimmer Biomet Holdings Inc was Initiated by Nomura to “Buy” on Mar 17, 2016.
Zimmer Biomet Holdings Inc. formerly Zimmer Holdings Inc. is a musculoskeletal healthcare company. The Company designs manufactures and markets orthopedic reconstructive products; sports medicine biologics extremities and trauma products; spine bone healing craniomaxillofacial and thoracic products; dental implants and related surgical products. The Company manages its operations through three geographic segments: the Americas comprising principally of the United States and includes other North Central and South American markets; Europe comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers and directly to dental practices and dental laboratories.